SCYNEXIS Inc (DE:135A)
NASDAQ:135A
135A Stock Chart & Stats
€0.64
€0.00(0.00%)
At close: 4:00 PM EST
€0.64
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.48 - €0.98
Previous CloseN/A
Volume0.00
Average Volume (3M)391.00
Market Cap
€31.45M
Enterprise Value€17.22M
Total Cash (Recent Filing)€40.11M
Total Debt (Recent Filing)€2.17M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
May 18, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding44,663,834
10 Day Avg. Volume800
30 Day Avg. Volume391
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.03Price Target Upside373.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€1.01M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMaterial deleveraging and a sizable equity base provide durable financial flexibility. Low debt reduces near-term refinancing risk and supports continued R&D, regulatory work, and commercialization spend over the next several months without immediate reliance on dilutive financing.
Approved Commercial Product And PipelineHaving an FDA‑approved oral antifungal creates a structural revenue platform and a clear commercialization pathway. Approval supports repeat prescription dynamics, provides credibility for partnerships, and enables label expansion and new formulation opportunities over a multimonth horizon.
Reduced Cash Burn / Improving Cash Flow TrendA large reduction in negative operating and free cash flow signals improving cash discipline and/or better commercial traction. This trend lengthens runway and lowers the odds of urgent financing needs, a durable operational improvement if sustained into the next reporting periods.
Bears Say
Highly Volatile RevenueExtreme swings in revenue undermine predictability for forecasting, capacity planning, and sustainable margin improvement. Such volatility suggests earnings are sensitive to episodic events or partner actions, raising execution and commercial risk over the coming months.
Negative Profitability And MarginsMaterial negative margins and ongoing losses constrain the company's ability to self‑finance growth or absorb setbacks. Continued negative EBITDA erodes equity and increases the probability of future capital raises that could dilute shareholders or redirect management focus from long‑term value creation.
Concentration Of Revenue SourcesDependence on a single approved product and collaboration payments concentrates commercial and execution risk. Outcomes hinge on prescription demand, reimbursement, and partner performance, leaving limited diversification and elevating structural revenue risk over the medium term.
SCYNEXIS News
135A FAQ
What was SCYNEXIS Inc’s price range in the past 12 months?
SCYNEXIS Inc lowest stock price was €0.48 and its highest was €0.98 in the past 12 months.
What is SCYNEXIS Inc’s market cap?
SCYNEXIS Inc’s market cap is €31.45M.
When is SCYNEXIS Inc’s upcoming earnings report date?
SCYNEXIS Inc’s upcoming earnings report date is May 18, 2026 which is in 51 days.
How were SCYNEXIS Inc’s earnings last quarter?
SCYNEXIS Inc released its earnings results on Mar 04, 2026. The company reported €0.217 earnings per share for the quarter, beating the consensus estimate of €0.11 by €0.107.
Is SCYNEXIS Inc overvalued?
According to Wall Street analysts SCYNEXIS Inc’s price is currently Undervalued.
Does SCYNEXIS Inc pay dividends?
SCYNEXIS Inc does not currently pay dividends.
What is SCYNEXIS Inc’s EPS estimate?
SCYNEXIS Inc’s EPS estimate is -0.11.
How many shares outstanding does SCYNEXIS Inc have?
SCYNEXIS Inc has 44,663,834 shares outstanding.
What happened to SCYNEXIS Inc’s price movement after its last earnings report?
SCYNEXIS Inc reported an EPS of €0.217 in its last earnings report, beating expectations of €0.11. Following the earnings report the stock price went up 0.773%.
Which hedge fund is a major shareholder of SCYNEXIS Inc?
Currently, no hedge funds are holding shares in DE:135A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.70%
12-Months-Change
Fundamentals
Return on Equity
-19.05%
Trailing 12-Months
Asset Growth
-34.88%
Trailing 12-Months
Company Description
SCYNEXIS Inc
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
135A Stock 12 Month Forecast
Average Price Target
€3.03
▲(373.83% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Options Prices
Currently, No data available
---